Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.70 |
| ▸ | LPL | P06858 | 8/20 | 0.70 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24770337 | 0.95 | LIPG (0.72) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL15197483 | 0.94 | LIPG (0.80) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL15197471 | 0.94 | LIPG (0.80) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL27254686 | 0.93 | LIPG (0.78) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL25799121 | 0.92 | LIPG (0.77) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL31667850 | 0.92 | LIPG (0.77) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL22025719 | 0.92 | LIPG (0.77) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL24353190 | 0.92 | LIPG (0.77) | LIPGLPLESR1ESR2IRAK4 | |
| SCHEMBL13700830 | 0.92 | LIPG (0.73) | LIPGLPLIRAK4DGAT1PDGFRB | |
| SCHEMBL30065945 | 0.92 | LIPG (0.73) | LIPGLPLIRAK4DGAT1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917914-B1 | Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11917914-B1 | Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230225206-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230225206-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917914-B1 | Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof | NFE2L2, ESR1, OR51E2 | LIPG 2250/4885LPL 2100/4885ESR1 2/4885 |
| US-20230225206-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | NFE2L2, ESR1, OR51E2 | LIPG 2250/4885LPL 2100/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.